1-4 of 4
Marc Botteman, MS, MA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 382.
https://doi.org/10.1182/blood-2019-123554
Published: 2019
Journal Articles

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Namita Joshi, PhD MS, BPharm, Xinyi Ng, Marc Botteman, MS, MA, Nanxin Li, Rachel Shah, BS, Nisha Jain, Nicole Lyn, Jun Su
Journal: Blood
Blood (2019) 134 (Supplement_1): 2122.
https://doi.org/10.1182/blood-2019-126774
Published: 2019
Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3520.
https://doi.org/10.1182/blood-2018-99-114993
Published: 2018
Journal Articles

Real-World Differences in Characteristics and Survival of Relapsed AML Patients with and without Transplant

Abdalla Aly, Saurabh Ray, Anuj Shah, PhD, Marc Botteman, MS, MA
Journal: Blood
Blood (2018) 132 (Supplement 1): 2297.
https://doi.org/10.1182/blood-2018-99-118621
Published: 2018